Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

DRUG5 trials

Sponsors

Array Biopharma, now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Advanced Multiple MyelomaAdvanced Solid TumorsMultiple MyelomaMultiple Myeloma, Plasma Cell LeukemiaPlasma Cell Leukemia

Phase 1

A Study of ARRY-520 in Patients With Advanced Cancer

CompletedNCT00462358

Array Biopharma, now a wholly owned subsidiary of PfizerAdvanced Solid Tumors

Start: 2007-04-30End: 2010-11-30Updated: 2020-09-28

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT00821249

PfizerMultiple Myeloma, Plasma Cell Leukemia

Start: 2009-01-31End: 2016-03-16Updated: 2020-10-19

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

CompletedNCT01248923

Array Biopharma, now a wholly owned subsidiary of PfizerMultiple Myeloma, Plasma Cell Leukemia

Start: 2010-12-31Updated: 2020-09-30

Phase 2

A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

CompletedNCT01989325

PfizerAdvanced Multiple Myeloma

Start: 2013-11-30End: 2016-05-31Updated: 2020-09-16

A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

CompletedNCT02092922

PfizerAdvanced Multiple Myeloma

Start: 2014-05-31End: 2017-09-05Updated: 2020-10-19

Related Papers

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

Cancer2017-08-1772 citations

The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.

Journal of Clinical Oncology2015-05-202 citations

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.

Journal of Clinical Oncology2015-05-201 citations